Key result
Levosimendan does not appear to improve survival for patients with acute severe heart failure in the intensive care unit, based on a review of available clinical trials.
Why the study?
Does levosimendan improve survival in patients with acute or decompensated severe heart failure in the intensive care unit?
Population
Patients with acute or decompensated severe heart failure in the intensive care unit
Comparison
Levosimendan vs Placebo or dobutamine
Design
Review
Authors
Loading...
No survival benefit with levosimendan in acute severe HF; leaves open optimal inotrope selection in the ICU.
Does levosimendan improve survival in patients with acute or decompensated severe heart failure in the intensive care unit?
Based on the largest available trials, levosimendan does not appear to improve survival in acute severe heart failure, challenging its routine use in the ICU.
Delaney et al. (2007) conducted a review in Acute or decompensated severe heart failure. Levosimendan vs. Placebo and dobutamine was evaluated on Survival. Levosimendan does not appear to improve survival for patients with acute severe heart failure in the intensive care unit, based on a review of available clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: